Gain Therapeutics to Present Long-Term Data on Rexaceract for Parkinson’s Disease
Event summary
- Gain Therapeutics will present long-term open-label data on rexaceract (GT-02287) at the International Congress of Parkinson’s Disease and Movement Disorders on October 7, 2026.
- Rexaceract is a GCase modulator in Phase 1b trials for Parkinson’s disease with or without GBA1 mutation.
- The poster presentation (E-Poster Number: 753) will be held in Seoul, Korea, from 12:00-12:10pm KST.
- Rexaceract has shown potential to slow or stop disease progression in preclinical models.
The big picture
Gain Therapeutics’ presentation at the International Congress of Parkinson’s Disease and Movement Disorders highlights the growing focus on allosteric small molecule therapies for neurodegenerative diseases. The company’s lead candidate, rexaceract, targets a critical enzyme linked to Parkinson’s, positioning it in a niche with high unmet medical need. Success in this space could attract further investment and partnerships, especially given the backing from prominent foundations and EU research programs.
What we're watching
- Clinical Progress
- Whether the long-term data on rexaceract will demonstrate sustained efficacy and safety in Parkinson’s patients.
- Regulatory Pathway
- The pace at which Gain Therapeutics advances rexaceract through Phase 1b and into Phase 2 trials.
- Market Positioning
- How Gain Therapeutics differentiates rexaceract in a competitive landscape for Parkinson’s disease treatments.
Related topics